Wyeth’s Pristiq Best-Case Launch Scenario Targets Menopause Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is re-inspecting the manufacturing facility cited in an “approvable” letter for Wyeth’s initial NDA for major depressive disorder.
You may also be interested in...
Wyeth Guayama Inspection Will Take Longer Than Anticipated
FDA’s inspection of the manufacturing facility is going to take “several more weeks,” firm announces.
Wyeth Guayama Inspection Will Take Longer Than Anticipated
FDA’s inspection of the manufacturing facility is going to take “several more weeks,” firm announces.
Wyeth’s Pristiq Deemed “Approvable” By FDA
Approval of Effexor XR follow-on is contingent upon inspection of firm's Puerto Rico manufacturing plant.